Small Airways Disease, Biomarkers and COPD: Where are We?

References

• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(4):347–365.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Eng J Med. 1968;278(25):1355–1360.
   PubMed Web of Science ®Google Scholar
• Koo H-K, Vasilescu DM, Booth S, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir Med. 2018;6(8):591–602.
   PubMed Web of Science ®Google Scholar
• Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Eng J Med. 1978;298(23):1277–1281.
   PubMed Web of Science ®Google Scholar
• McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Eng J Med. 2011;365(17):1567–1575.
   PubMed Web of Science ®Google Scholar
• Hogg JC, McDonough JE, Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013;143(5):1436–1443.
   PubMed Web of Science ®Google Scholar
• Young AL, Bragman FJS, Rangelov B, et al. Disease progression modeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;201(3):294–302.
   Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192.
   PubMed Web of Science ®Google Scholar
• Timmins SC, Diba C, Farrow CE, et al. The relationship between airflow obstruction, emphysema extent, and small airways function in COPD. Chest. 2012;142(2):312–319.
   PubMed Web of Science ®Google Scholar
• Young AL, Bragman FJS, Rangelov B, et al. Disease progression modeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(3):294–302.
   PubMed Web of Science ®Google Scholar
• Molfino NA, Coyle AJ. Gene-environment interactions in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):491–497.
   PubMedGoogle Scholar
• Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122(8):2749–2755.
   PubMed Web of Science ®Google Scholar
• Yakar HI, Gunen H, Pehlivan E, Aydogan S. The role of tuberculosis in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:323–329.
   PubMed Web of Science ®Google Scholar
• Sarkar M, Madabhavi I, Kumar K. Tuberculosis associated chronic obstructive pulmonary disease. Clin Respir J. 2017;11(3):285–295.
   PubMed Web of Science ®Google Scholar
• van Kampen SC, Wanner A, Edwards M, et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Health. 2018;3(4):e000745–e000745.
   PubMed Web of Science ®Google Scholar
• Guo-Parke H, Linden D, Weldon S, Kidney JC, Taggart CC. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease, progression, and exacerbation. Front Immunol. 2020;11.
   PubMed Web of Science ®Google Scholar
• Chow DP, Chung W Role of viral infections in asthma and chronic obstructive pulmonary disease. http://dxdoiorg/101165/rcmb2006-0199TR. 2012.
   Google Scholar
• Singanayagam A, Joshi PV, Mallia P, Johnston SL. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 2012;10(1):27.
   PubMedGoogle Scholar
• Stockley JA, Ismail AM, Hughes SM, Edgar R, Stockley RA, Sapey E. Maximal mid-expiratory flow detects early lung disease in α. Eur Respir J. 2017;49:3.
   Web of Science ®Google Scholar
• McFadden ER, Linden DA. A reduction in maximum mid-expiratory flow rate: a spirographic manifestation of small airway disease. Am J Med. 1972;52(6):725–737.
   PubMed Web of Science ®Google Scholar
• Stockley JA, Cooper BG, Stockley RA, Sapey E. Small airways disease: time for a revisit? Int J Chron Obstruct Pulmon Dis. 2017;12:2343–2353.
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43(4):1051–1058.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Bhakta NR, Wilson CG, et al. New spirometry indices for detecting mild airflow obstruction. Sci Rep. 2018;8(1):17484.
   PubMedGoogle Scholar
• Bhatt SP, Bodduluri S, Raghav V, et al. The peak index: spirometry metric for airflow obstruction severity and heterogeneity. Ann Am Thorac Soc. 2019;16(8):982–989.
   PubMed Web of Science ®Google Scholar
• Bickel S. Impulse Oscillometry. Adv Respir Med. 2019;87(4).
   Web of Science ®Google Scholar
• Wei X, Shi Z, Cui Y, et al. Impulse oscillometry system as an alternative diagnostic method for chronic obstructive pulmonary disease. Medicine. 2017;96:46.
   Web of Science ®Google Scholar
• Schermer T, Malbon W, Newbury W. Spirometry and Impulse Oscillometry (IOS) for Detection of Respiratory Abnormalities in Metropolitan Firefighters. Respirology. 2010;15:6.
   PubMed Web of Science ®Google Scholar
• Mondal P, Yirinec A, Midya V. Diagnostic value of spirometry vs impulse oscillometry: a comparative study in children with sickle cell disease. Pediatr Pulmonol. 2019;54:9.
   Web of Science ®Google Scholar
• Midya V. Advantage of impulse oscillometry over spirometry to diagnose chronic obstructive pulmonary disease and monitor pulmonary responses to bronchodilators: an observational study. SAGE Open Med. 2015;3.
   Google Scholar
• Crim C, Celli B, Edwards LD, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med. 2011;105(7):1069–1078.
   PubMed Web of Science ®Google Scholar
• Desiraju K, Agrawal A. Impulse oscillometry: the state-of-art for lung function testing. Lung India. 2016;33(4):410–416.
   PubMedGoogle Scholar
• Horsley AR, Gustafsson PM, Macleod KA, et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. Thorax. 2008;63:135.
   PubMed Web of Science ®Google Scholar
• Aurora P, Bush A, Gustafsson P, et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med. 2005;171(3):249–256.
   PubMed Web of Science ®Google Scholar
• Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003;22(6):972–979.
   PubMed Web of Science ®Google Scholar
• Horsley A. Lung clearance index in the assessment of airways disease. Respir Med. 2009;103(6):793–799.
   PubMed Web of Science ®Google Scholar
• Vermeulen F, Proesmans M, Boon M, Havermans T, De Boeck K. Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax. 2014;69(1):39–45.
   PubMed Web of Science ®Google Scholar
• Poncin W, Lebecque P. [Lung clearance index in cystic fibrosis]. Rev Mal Respir. 2019;36(3):377–395.
   PubMed Web of Science ®Google Scholar
• Perrem L, Rayment JH, Ratjen F. The lung clearance index as a monitoring tool in cystic fibrosis: ready for the clinic? Curr Opin Pulm Med. 2018;24(6):579–585.
   PubMed Web of Science ®Google Scholar
• Daynes E, Soares M, Greening N, Owers-Bradley J, Singh S, Siddiqui S. P231 The feasibility and repeatability of the lung clearance index via multiple breath washout measurements in stable chronic obstructive pulmonary disease. 2018.
   Google Scholar
• Fähndrich S, Lepper PM, Trudzinski F, Seibert M, Wagenpfeil S, Bals R. Lung Clearance Index is Increased in Patients with COPD – LCI Measurements in the Daily Routine | OMICS International. J Pulmonary Respir Med. 2016;6(3):1.
   Google Scholar
• McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648.
   PubMed Web of Science ®Google Scholar
• Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63(9):768–774.
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Pinto-Plata V, Morse D, Celli BR, Rosas IO. The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest. 2012;142(4):1027–1034.
   PubMed Web of Science ®Google Scholar
• Seiler CL, JuM S, Kotandeniya D, et al. Inhalation exposure to cigarette smoke and inflammatory agents induces epigenetic changes in the lung. Sci Rep. 2020;10(1):11290.
   PubMed Web of Science ®Google Scholar
• Koutsokera A, Kostikas K, Nicod LP, Fitting J-W. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respir Res. 2013;14(1):111.
   PubMedGoogle Scholar
• Holz O, Waschki B, Roepcke S, et al. Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD. BMC Pulm Med. 2014;14:30.
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–721.
   PubMed Web of Science ®Google Scholar
• Hiemstra PS, McCray PB, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J. 2015;45(4):1150.
   PubMed Web of Science ®Google Scholar
• Gohy ST, Hupin C, Pilette C, Ladjemi MZ. Chronic inflammatory airway diseases: the central role of the epithelium revisited. Clin Exp Allergy. 2016;46(4):529–542.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Timens W. The Pathology of Chronic Obstructive Pulmonary Disease. Ann Rev Pathol. 2009;4(1):435–459.
   PubMedGoogle Scholar
• Araya J, Cambier S, Markovics JA, et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest. 2007;117(11):3551–3562.
   PubMed Web of Science ®Google Scholar
• Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010;363(23):2233–2247.
   PubMed Web of Science ®Google Scholar
• Gindele JA, Kiechle T, Benediktus K, et al. Intermittent exposure to whole cigarette smoke alters the differentiation of primary small airway epithelial cells in the air-liquid interface culture. Sci Rep. 2020;10(1):6257.
   PubMed Web of Science ®Google Scholar
• Lakind JS, Holgate ST, Ownby DR, et al. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers. 2007;12(5):445–467.
   PubMed Web of Science ®Google Scholar
• Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: a Steroid-Inducible Immunomodulatory Protein That Founded the Secretoglobin Superfamily. Endocr Rev. 2007;28(7):707–725.
   PubMed Web of Science ®Google Scholar
• Stenberg H, Wadelius E, Moitra S, et al. Club cell protein (CC16) in plasma, bronchial brushes, BAL and urine following an inhaled allergen challenge in allergic asthmatics. Biomarkers. 2018;23(1):51–60.
   PubMed Web of Science ®Google Scholar
• Van Miert E, Dumont X, Bernard A. CC16 as a marker of lung epithelial hyperpermeability in an acute model of rats exposed to mainstream cigarette smoke. Toxicol Lett. 2005;159(2):115–123.
   PubMed Web of Science ®Google Scholar
• Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax. 2014;69(7):666.
   PubMed Web of Science ®Google Scholar
• Guerra S, Halonen M, Vasquez MM, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med. 2015;3(8):613–620.
   PubMed Web of Science ®Google Scholar
• Park HY, Churg A, Wright JL, et al. Club Cell Protein 16 and Disease Progression in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013;188(12):1413–1419.
   PubMed Web of Science ®Google Scholar
• Mulrennan S, Baltic S, Aggarwal S, et al. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep. 2015;5:8931.
   PubMed Web of Science ®Google Scholar
• Sukkar MB, Wood LG, Tooze M, et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J. 2012;39(3):721.
   PubMed Web of Science ®Google Scholar
• Wu L, Ma L, Nicholson LFB, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. 2011;105(3):329–336.
   PubMed Web of Science ®Google Scholar
• Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Müller M. Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol. 1998;44(7):1147–1157.
   PubMed Web of Science ®Google Scholar
• Dahlin K, Mager EM, Allen L, et al. Identification of Genes Differentially Expressed in Rat Alveolar Type I Cells. Am J Respir Cell Mol Biol. 2004;31(3):309–316.
   PubMed Web of Science ®Google Scholar
• Shirasawa M, Fujiwara N, Hirabayashi S, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes to Cells. 2004;9(2):165–174.
   PubMed Web of Science ®Google Scholar
• Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173(9):1008–1015.
   PubMed Web of Science ®Google Scholar
• Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol. 2010;2010:917108.
   PubMedGoogle Scholar
• Oczypok EA, Perkins TN, Oury TD. All the “RAGE” in lung disease: the receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev. 2017;23:40–49.
   PubMed Web of Science ®Google Scholar
• Hoonhorst SJM. Lo Tam Loi AT, Pouwels SD, et al. Advanced glycation endproducts and their receptor in different body compartments in COPD. Respir Res. 2016;17(1):46.
   PubMedGoogle Scholar
• Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res. 2011;12(1):37.
   PubMedGoogle Scholar
• Haider SH, Oskuei A, Crowley G, et al. Receptor for advanced glycation end-products and environmental exposure related obstructive airways disease: a systematic review. Eur Respir Rev. 2019;28(151):180096.
   PubMed Web of Science ®Google Scholar
• Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37(3):516.
   PubMed Web of Science ®Google Scholar
• Zhang H, Tasaka S, Shiraishi Y, et al. Role of Soluble Receptor for Advanced Glycation End Products on Endotoxin-induced Lung Injury. Am J Respir Crit Care Med. 2008;178(4):356–362.
   PubMed Web of Science ®Google Scholar
• Sanders KA, Delker DA, Huecksteadt T, et al. RAGE is a Critical Mediator of Pulmonary Oxidative Stress, Alveolar Macrophage Activation and Emphysema in Response to Cigarette Smoke. Sci Rep. 2019;9(1):231.
   PubMedGoogle Scholar
• Robinson AB, Johnson KD, Bennion BG, Reynolds PR. RAGE signaling by alveolar macrophages influences tobacco smoke-induced inflammation. Am J Physiol Lung Cell Mol Physiol. 2012;302(11):L1192–L1199.
   PubMed Web of Science ®Google Scholar
• Carolan BJ, Hughes G, Morrow J, et al. The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res. 2014;15(1):127.
   PubMedGoogle Scholar
• Cheng DT, Kim DK, Cockayne DA, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(8):948–957.
   PubMed Web of Science ®Google Scholar
• Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):e72–e91.
   PubMed Web of Science ®Google Scholar
• Alessi M-C J-VI. PAI-1 and the Metabolic Syndrome. Arterioscler Thromb Vasc Biol. 2006;26(10):2200–2207.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res. 2005;66(2):276–285.
   PubMed Web of Science ®Google Scholar
• Waschki B, Watz H, Holz O, et al. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. Int J Chron Obstruct Pulmon Dis. 2017;12:981–987.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang T, Li D, et al. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2369–2376.
   PubMed Web of Science ®Google Scholar
• Lazar MH, Christensen PJ, Du M, et al. Plasminogen activator inhibitor–1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol. 2004;31(6):672–678.
   PubMed Web of Science ®Google Scholar
• Xiao W, Hsu Y-P, Ishizaka A, Kirikae T, Moss RB, Cathelicidin S. Urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and Asthma Inflammation. Chest. 2005;128(4):2316–2326.
   PubMed Web of Science ®Google Scholar
• To M, Takagi D, Akashi K, et al. Sputum plasminogen activator inhibitor-1 elevation by oxidative stress-dependent nuclear factor-κB activation in COPD. Chest. 2013;144(2):515–521.
   PubMed Web of Science ®Google Scholar
• Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454.
   PubMedGoogle Scholar
• Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173–180.
   PubMed Web of Science ®Google Scholar
• Wygrecka M, Markart P, Ruppert C, et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J. 2007;29(6):1105.
   PubMed Web of Science ®Google Scholar
• Ueno M, Maeno T, Nomura M, et al. Hypoxia-inducible factor-1α mediates TGF-β-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2011;300(5):L740–L752.
   PubMed Web of Science ®Google Scholar
• Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 2003;58(4):348–351.
   PubMed Web of Science ®Google Scholar
• Loffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011;38(1):191.
   PubMed Web of Science ®Google Scholar
• Ishii T, Abboud RT, Wallace AM, et al. Alveolar macrophage proteinase/antiproteinase expression in lung function and emphysema. Eur Respir J. 2014;43(1):82.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med. 2003;97(6):634–639.
   PubMed Web of Science ®Google Scholar
• Higashimoto Y, Yamagata Y, Iwata T, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J. 2005;25(5):885.
   PubMed Web of Science ®Google Scholar
• Owen CA, Hu Z, Barrick B, Shapiro SD. Inducible expression of tissue inhibitor of metalloproteinases–resistant matrix metalloproteinase-9 on the cell surface of neutrophils. Am J Respir Cell Mol Biol. 2003;29(3):283–294.
   PubMed Web of Science ®Google Scholar
• Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med. 2005;99(6):703–710.
   PubMed Web of Science ®Google Scholar
• Ostridge K, Williams N, Kim V, et al. Relationship between pulmonary matrix metalloproteinases and quantitative CT markers of small airways disease and emphysema in COPD. Thorax. 2016;71(2):126.
   PubMed Web of Science ®Google Scholar
• Wells JM, Parker MM, Oster RA, et al. Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene. JCI Insight. 2018;3(22):e123614.
   PubMed Web of Science ®Google Scholar
• Xu X, Jackson PL, Tanner S, et al. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One. 2011;6(1):e15781–e15781.
   PubMed Web of Science ®Google Scholar
• B B-gh B, Nowicka A, Kuznar-Kaminska B, Szczepanik A. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol. 2008;59:145–152.
   Web of Science ®Google Scholar
• Linder R, Rönmark E, Pourazar J, Behndig A, Blomberg A, Lindberg A. Serum metalloproteinase-9 is related to COPD severity and symptoms - cross-sectional data from a population based cohort-study. Respir Res. 2015;16(1):28.
   PubMedGoogle Scholar
• Uysal P, Uzun H. Relationship between circulating serpina3g, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 and −2 with chronic obstructive pulmonary disease severity. Biomolecules. 2019;9(2):62.
   PubMed Web of Science ®Google Scholar
• Lowrey GE, Henderson N, Blakey JD, Corne JM, Johnson SRMMP-9. protein level does not reflect overall MMP activity in the airways of patients with COPD. Respir Med. 2008;102(6):845–851.
   PubMed Web of Science ®Google Scholar
• H RP I, Demedts I, Brusselle GG, et al. Matrix metalloproteinases −8, −9 and −12 in smokers and patients with Stage 0 COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(3):369–370.
   PubMedGoogle Scholar
• Vernooy JHJ, Lindeman JHN, Jacobs JA, Hanemaaijer R, Wouters EFM. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest. 2004;126(6):1802–1810.
   PubMed Web of Science ®Google Scholar
• Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002.
   PubMed Web of Science ®Google Scholar
• Demedts IK, Morel-Montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax. 2006;61(3):196.
   PubMed Web of Science ®Google Scholar
• LaPan P, Brady J, Grierson C, et al. Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum. BMC Pulm Med. 2010;10:40.
   PubMed Web of Science ®Google Scholar
• Imai K, Dalal SS, Chen ES, et al. Human Collagenase (Matrix Metalloproteinase-1) Expression in the Lungs of Patients with Emphysema. Am J Respir Crit Care Med. 2001;163(3):786–791.
   PubMed Web of Science ®Google Scholar
• Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009;361(27):2599–2608.
   PubMed Web of Science ®Google Scholar
• Babusyte A, Stravinskaite K, Jeroch J, Lötvall J, Sakalauskas R, Sitkauskiene B. Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res. 2007;8(1):81.
   PubMedGoogle Scholar
• Wallace AM, Sandford AJ, English JC, et al. Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. COPD. 2008;5(1):13–23.
   PubMedGoogle Scholar
• Filippov S, Caras I, Murray R, et al. Matrilysin-dependent elastolysis by human macrophages. J Exp Med. 2003;198(6):925–935.
   PubMed Web of Science ®Google Scholar
• Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases a and b, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117(3):684–694.
   PubMed Web of Science ®Google Scholar
• Sng JJ, Prazakova S, Thomas PS, Herbert CMMP-8. MMP-9 and neutrophil elastase in peripheral blood and exhaled breath condensate in COPD. COPD. 2017;14(2):238–244.
   PubMedGoogle Scholar
• McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir J. 2014;1. doi:10.3402/ecrj.v3401.25898
   Google Scholar
• Subramaniam K, Kumar H, Tawhai MH. Evidence for age-dependent air-space enlargement contributing to loss of lung tissue elastic recoil pressure and increased shear modulus in older age. J Appl Physiol. 2017;123(1):79–87.
   PubMed Web of Science ®Google Scholar
• Lee KW, Chung SY, Yang I, Lee Y, Ko EY, Park MJ. Correlation of aging and smoking with air trapping at thin-section CT of the lung in asymptomatic subjects. Radiology. 2000;214(3):831–836.
   PubMed Web of Science ®Google Scholar
• Fukuchi Y. The aging lung and chronic obstructive pulmonary disease: similarity and difference. Proc Am Thorac Soc. 2009;6(7):570–572.
   PubMedGoogle Scholar
• Thomas ET, Guppy M, Straus SE, Bell KJL, Glasziou P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. 2019.
   Google Scholar
• Verbeken EK, Cauberghs M, Mertens I, Clement J. The senile lung. Comparison with normal and emphysematous lungs. 1. Structural aspects. Chest. 1992;101(3):793–799.
   PubMed Web of Science ®Google Scholar
• Teramoto S, Ishii M Aging, the Aging Lung, and Senile Emphysema Are Different. http://dxdoiorg/101164/ajrccm1752197. 2012.
   Google Scholar
• Mercado N, Ito K, Barnes PJ. Accelerated ageing of the lung in COPD: new concepts. 2015.
   Google Scholar
• Walters MS, De BP, Salit J, et al. Smoking accelerates aging of the small airway epithelium. Respir Res. 2014;15:94.
   PubMed Web of Science ®Google Scholar
• Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–1051.
   PubMed Web of Science ®Google Scholar
• Martinez CH, Diaz AA, Meldrum C, et al. Age and small airway imaging abnormalities in subjects with and without airflow obstruction in SPIROMICS. Am J Respir Crit Care Med. 2017;195(4):464–472.
   PubMed Web of Science ®Google Scholar
• van der Molen T, Postma DS, Martin RJ, et al. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulm Med. 2016;16(1):80.
   PubMedGoogle Scholar
• Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010;65(7):897–902.
   PubMed Web of Science ®Google Scholar
• Singh D, Nicolini G, Bindi E, et al. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med. 2014;14:43.
   PubMed Web of Science ®Google Scholar